

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Announcement/2025-26

Date: 21.02.2026

**BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001**

**National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla complex
Bandra(E) Mumbai- 400051**

Code No: 531146

Symbol: MEDICAMEQ

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), read with Schedule III of the Listing Regulations, it is hereby informed that the Company has on 27th January, 2026, received a cautionary letter (e-mail) from National Stock Exchange of India Ltd. ('NSE') for observation(s) reported by Secretarial Auditor in Secretarial Compliance Report submitted for financial year ended 31st March, 2025.

The details as required under Schedule III of the Listing Regulations read with SEBI Master circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, are attached herewith as Annexure - I.

Kindly take the information on record.

Thanking You

**Yours truly,
For Medicamen Biotech Limited**

**Parul Choudhary
Company Secretary
ACS: 44157**

Annexure-I

Details as required under Schedule III of the Listing Regulations read with SEBI Master circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024

Particulars	Details of Cautionary Letter
Name of the authority	National Stock Exchange of India Ltd. ('NSE')
Nature and details of the action(s) taken or order(s) passed;	NSE has issued cautionary letter (e-mail) for observation(s) reported by Secretarial Auditor in Secretarial Compliance Report submitted for financial year ended March 2025.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	27th January, 2026.
Details of the violation(s)/contravention(s) committed or alleged to be committed;	The Secretarial Auditor had reported few observations in the Annual Secretarial Compliance Report. Considering the aforesaid, the Company has been advised to be careful in future to avoid recurrence of such lapses and adhere to the requirements of the applicable provisions/regulations as per the Listing Regulations.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	There is no impact on the financials, operations, or other activities of the Company.